Pharmaceutical Contract Manufacturing Global Market - Forecast to 2025

Publishing Date : March, 2019
Report Code : HCPH0113
Price:
Single license $5,400
Site license $7,200
Global license $9,000


Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing and formulation due to rise in population, increasing in diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations, merger and acquisitions. Pharmaceutical companies are increasing their dependence on contract manufacturing organizations due to lack of having well equipped manufacturing facilities, advanced technologies, high containment capabilities or though they have the facilities, due to insufficient time and to have backup manufacturing, pharmaceutical companies are outsourcing. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF). APIs based on molecule size are categorized into biologics/large and synthetic/small molecules. According to IQ4I analysis, synthetic molecules occupy major share of XX% to XX% and the biologics accounts for share of XX% to XX% in API market. One of the major reasons for increasing in synthetic API market is the availability of small molecule drugs for all the major diseases and large number of small molecule drugs in pipeline, which is expected to enter the market in coming years.

According to IQ4I analysis, the Pharmaceutical contract manufacturing global market is expected to grow at mid single digit CAGR to reach $95,904.9 million by 2025. Pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing market holds the largest share in 2018 and is expected to grow at mid single digit CAGR from 2018 to 2025 due to government initiatives, increase in a number of API manufacturers, increasing availability of APIs for all the diseases, aging population, rise in chronic diseases, research and manufacturing of new drugs and demand for generics. FDF manufacturing is the fastest growing segment with strong CAGR from 2018 to 2025, due to high profit margin for pharma contract manufacturers and most of the CMO companies in APAC regions are shifting from API to FDF manufacturing.

The API manufacturing market by customer base is sub segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment is accounted for the largest revenue in 2018 and is expected to grow at a strong CAGR from 2018 to 2025, due to the patent expiries of branded drugs, low cost of generic medicines. The branded API segment is projected to grow at a CAGR of 4.0% from 2018 to 2025.

The FDF manufacturing market by dosage form is classified into solid dosage form, injectable dosage form, and semi-solid liquid, gaseous dosage form. Solid dosage form is accounted for the largest revenue in 2018 and is expected to grow at a CAGR of 4.0% from 2018 to 2025, due to changing consumer demands, advent and progress of newer dosage forms and ever evolving regulations. The injectable dosage form is a fastest growing segment and expected to grow at a CAGR from 2018 to 2025 due to its direct infusion to the body, and onset of action of drugs is faster. Hence, it is suitable for emergency conditions.

Pharmaceutical contract manufacturing by phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing holds the highest revenue in 2018 and expected to grow at a mid single digit CAGR from 2018 to 2025, due to huge demand for commercial API production, patent expiry increases commercial manufacturing of API and FDF and increase in outsourcing of generic APIs. Whereas, clinical manufacturing is expected to grow at a high single digit CAGR from 2018 to 2025, due to increase in the number of pipeline drugs where XX% of the APIs are synthetic API, clinical phase 2 and 3 projects requiring cGMP facilities and increase in outsourcing by innovator pharma companies due to low cost manufacturing and shorter timelines. Also, clinical manufacturing play a significant role in securing client relationships that can lead to commercial scale manufacturing contracts.

Pharmaceutical contract manufacturing market by application is segmented as Oncology, Central nervous system, Cardiovascular disorder, Infectious diseases, Pulmonary disorders, Metabolic disorder, Gastrointestinal disorders, Musculoskeletal disorders, Genitourinary disorders, Endocrinology and other applications (acute pain, chronic pain and post-surgical, dental, ENT, autoimmune disorder). Among these applications, Infectious disease segment accounted for the largest revenue in 2018 due to increase in global HIV pandemic causes about one million deaths every year, emergence of severe acute respiratory syndrome (SARs) and viral hemorrhagic fever. The Oncology segment is a fastest growing application market during the forecasting period, due to increase in incidence of breast and lung cancer, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and FDA approvals.

Pharmaceutical contract manufacturing market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others) and Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. In North America, U.S. and Canada are the most prominent countries in which U.S. occupies the largest revenue, due to expansion of regional market includes developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing government focus on generic drugs, rising demands for specialty of drugs and technological advancements. Asia-Pacific region is expected to grow at a strong CAGR of 8.4% from 2018 to 2025. Mainly India and China are concentrated more due to low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of large number of domestic and international players, and concentration of CMO companies.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
    • U.S.
    • Rest of North America
  •  Europe
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of APAC
  • Rest of the World (RoW)
    • Brazil
    • Rest of Latin America
    • Middle East and Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASED TREND OF OUTSOURCING
        • 3.3.1.2     HIGH UPTAKE OF SMALL MOLECULES ACROSS DIVERSE THERAPEUTICS
        • 3.3.1.3     PATENT EXPIRATION OF SMALL MOLECULES DRUGS
        • 3.3.1.4     ADVANCED TECHNOLOGIES IN API AND FDF MANUFACTURING
        • 3.3.1.5     INCREASING DEALS AND INVESTMENTS
        • 3.3.1.6     GENERICS DRIVE INJECTABLE MARKET OPPORTUNITY
        • 3.3.1.7     INCREASING CHRONIC AND AUTOIMMUNE DISEASES
        • 3.3.1.8     INCREASE IN GERIATRIC AND AGED POPULATION
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     CONTAMINATION IN THE MANUFACTURING
        • 3.3.2.2     PRICING PRESSURE FOR PHARMACEUTICAL CONTRACT MANUFACTURING
        • 3.3.2.3     REQUIREMENT OF HIGHLY SKILLED TECHNICIANS
        • 3.3.2.4     INCREASING BIOLOGICS APPROVALS AND ADOPTION IN DISEASE MANAGEMENT
        • 3.3.2.5     STRINGENT REGULATORY REQUIREMENTS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 14644-1 CLEAN ROOM STANDARDS
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     MEXICO
      • 3.4.5     EUROPE
      • 3.4.6     JAPAN
      • 3.4.7     CHINA
      • 3.4.8     INDIA
      • 3.4.9     AUSTRALIA
      • 3.4.10     SOUTH KOREA
      • 3.4.11     LATIN AMERICA
      • 3.4.12     MIDDLE EAST
    • 3.5     PORTER’S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     BARGAINING POWER OF SUPPLIERS
      • 3.5.4     BARGAINING POWER OF BUYERS
      • 3.5.5     COMPETITIVE RIVALRY
    • 3.6     SUPPLY CHAIN ANALYSIS
    • 3.7     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.7.1     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS
      • 3.7.2     MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR PLAYERS
      • 3.7.3     MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR PLAYERS
    • 3.8     TECHNOLOGICAL ADVANCEMENTS
      • 3.8.1     ADVANCED TECHNOLOGIES FOR API MANUFACTURING
      • 3.8.2     ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING
    • 3.9     DIFFERENTIATED CAPABILITIES
      • 3.9.1     HPAPI
        • 3.9.1.1     SELECTED TOP SELLING HPAPI
      • 3.9.2     CONTINUOUS FLOW MANUFACTURING
      • 3.9.3     CRYOGENIC MANUFACTURING PROCESS
    • 3.10     CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET
    • 3.11     PATENT EXPIRY AND ANDA APPROVALS
    • 3.12     DRUG MASTER FILING (DMF)
    • 3.13     COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS
    • 3.14     COMPANIES ACQUISITION, MERGER AND INVESTMENTS
    • 3.15     API PRICING
    • 3.16     GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME
    • 3.17     COST OF MANUFACTURING FACILITY
    • 3.18     FDA APPROVED MANUFACTURING FACILITY
    • 3.19     NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
    • 3.20     CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
      • 3.20.1     INDIA
      • 3.20.2     CHINA
    • 3.21     PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE
  • 4     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     API MANUFACTURING
      • 4.2.1     BRANDED API MANUFACTURING
      • 4.2.2     GENERIC API MANUFACTURING
    • 4.3     FINISHED DOSAGE FORM (FDF) MANUFACTURING
      • 4.3.1     SOLID DOSAGE FORMS
      • 4.3.2     INJECTABLES DOSAGE FORMS
      • 4.3.3     SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS
  • 5     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PHASE
    • 5.1     INTRODUCTION
    • 5.2     CLINICAL MANUFACTURING
    • 5.3     COMMERCIAL MANUFACTURING
  • 6     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     ONCOLOGY
    • 6.3     CENTRAL NERVOUS SYSTEM
    • 6.4     CARDIOVASCULAR DISORDERS
    • 6.5     INFECTIOUS DISEASES
    • 6.6     PULMONARY DISORDERS
    • 6.7     METABOLIC DISORDERS
    • 6.8     GASTROINTESTINAL DISORDERS
    • 6.9     MUSCULOSKELETAL DISORDERS
    • 6.1     GENITOURINARY DISORDERS
    • 6.11     ENDOCRINOLOGY
    • 6.12     OTHER APPLICATIONS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     INDIA
      • 7.4.3     JAPAN
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST & OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     ACQUISITION, MERGER & COLLABORATION
    • 8.3     EXPANSION AND INVESTMENT
    • 8.4     REGULATORY APPROVAL
    • 8.5     SERVICE LAUNCH AND OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ABBVIE INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AENOVA HOLDING GMBH
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIAL
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     ALBANY MOLECULAR RESEARCH INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     ALMAC GROUP
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     CAMBREX CORPORATION
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     FAMAR S.A.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     GLAXOSMITHKLINE PLC
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     LONZA GROUP LTD
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     THERMO FISHER SCIENTIFIC (PATHEON N.V.)
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.1     PFIZET INC (PFIZER CENTERONE)
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     RECIPHARM AB
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS
    • 9.12     WUXI STA PHARMACEUTICALS LTD (WUXI APPTEC)
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     PRODUCT PORTFOLIO
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     BUSINESS STRATEGY
      • 9.12.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 2     CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, (2017-2025) ($MN)
      • TABLE 3     PATENT EXPIRY OF SYNTHETIC SMALL MOLECULE DRUGS, (2016 – 2021)
      • TABLE 4     ANDA APPROVALS, (2017 – 2018)
      • TABLE 5     SMALL MOLECULES API DMF FILED BY COMPANIES, (2017 – 2018)
      • TABLE 6     COLLABORATIONS, (2016 – 2019)
      • TABLE 7     ACQUISITION AND MERGER, (2017 – 2019)
      • TABLE 8     INVESTEMENTS, (2016 – 2018)
      • TABLE 9     API PRICING OF MAJOR SMALL MOLECULES
      • TABLE 10     GLOBAL PHARMACEUTICALS API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2018)
      • TABLE 11     GLOBAL PHARMACEUTICAL API PRODUCTION, BY APPLICATION, (2017-2025) (TONS)
      • TABLE 12     GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2017-2025) (MILLION LITRES)
      • TABLE 13     GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2017-2025) (MILLION LITRES)
      • TABLE 14     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
      • TABLE 15     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 16     API MANUFACTURING GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 17     API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 18     BRANDED API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 19     GENERIC API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 20     FDF MANUFACTURING GLOBAL MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
      • TABLE 21     FDF MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 22     SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 23     INJECTABLES DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 24     SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 25     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
      • TABLE 26     CLINICAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 27     COMMERCIAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 28     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 29     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 30     CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 31     CARDIOVASCULAR DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 32     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 33     PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 34     METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 35     GASTROINTESTINAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 36     MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 37     GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 38     ENDOCRINOLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 39     OTHER APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 40     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 41     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
      • TABLE 42     NORTH AMERICA API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 43     NORTH AMERICA FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
      • TABLE 44     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
      • TABLE 45     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 46     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 47     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
      • TABLE 48     EUROPE API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 49     EUROPE FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
      • TABLE 50     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
      • TABLE 51     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 52     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 53     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
      • TABLE 54     APAC API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 55     APAC FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
      • TABLE 56     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
      • TABLE 57     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 58     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 59     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
      • TABLE 60     ROW API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 61     ROW FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
      • TABLE 62     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
      • TABLE 63     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 64     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 65     ACQUISITION, MERGER & COLLABORATION (2016-2018)
      • TABLE 66     EXPANSION AND INVESTMENT (2016-2018)
      • TABLE 67     REGULATORY APPROVAL (2017-2018)
      • TABLE 68     SERVICE LAUNCH AND OTHERS (2016-2018)
      • TABLE 69     ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 70     ABBVIE INC.: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 71     ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 72     CAMBREX: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 73     CAMBREX : TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 74     GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 75     GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 76     GSK :TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 77     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 78     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 79     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 80     THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 81     THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 82     THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 83     PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 84     PFIZER INC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 85     PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 86     RECIPHARM AB: TOTAL REVENUE AND R&D EXPENSES (2016-2017) ($MN)
      • TABLE 87     RECIPHARM AB: TOTAL REVENUE, BY SEGMENT (2015-2017) ($MN)
      • TABLE 88     RECIPHARM AB: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)

      LIST OF FIGURES

      • FIGURE 1     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET
      • FIGURE 3     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
      • FIGURE 11     API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
      • FIGURE 12     FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
      • FIGURE 13     CONTRACT MANUFACTURING COMPANY CAPABILITIES
      • FIGURE 14     CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, 2018 ($MN)
      • FIGURE 15     PATENT EXPIRY OF SMALL MOLECULES (2016-2021)
      • FIGURE 16     PATENT EXPIRY (2019-2021) AND ANDA APPROVALS (2017-2018), BY APPLICATION SHARE (%)
      • FIGURE 17     PHARMACEUTICAL API PRODUCTION BY APPLICATION (2018), IN-HOUSE V/S CMO (2017 – 2025) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2018) (LITRES)
      • FIGURE 18     GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2017 – 2025) (TONS), API CMO MARKET SHARE BY REGION (2018) (%)
      • FIGURE 19     FDA APPROVED MANUFACTURING FACILITY BY COUNTRY (NO’S)
      • FIGURE 20     INDIA V/S CHINA
      • FIGURE 21     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PRODUCT (2018 V/S 2025) (%)
      • FIGURE 22     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 23     API MANUFACTURING GLOBAL MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 24     API MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 25     FDF MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2018 V/S 2025) (%)
      • FIGURE 26     FDF MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 27     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
      • FIGURE 28     CLINICAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 29     COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 30     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY APPLICATION (2018 V/S 2025) (%)
      • FIGURE 31     CARDIOVASCULAR DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 32     PULMONARY DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 33     METABOLIC DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 34     GASTROINTESTINAL DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 35     ENDOCRINOLOGY GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 36     OTHER APPLICATION GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 37     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN), CAGR (%)
      • FIGURE 38     PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY GEOGRAPHY (2018) (%)
      • FIGURE 39     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
      • FIGURE 40     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
      • FIGURE 41     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 42     NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 43     U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 44     U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 45     REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 46     REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 47     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
      • FIGURE 48     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
      • FIGURE 49     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 50     EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 51     GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 52     GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 53     FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 54     FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 55     ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 56     ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 57     REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 58     REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 59     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
      • FIGURE 60     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
      • FIGURE 61     APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 62     APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 63     CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 64     CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 65     INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 66     INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 67     JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 68     JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 69     REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 70     REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 71     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
      • FIGURE 72     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
      • FIGURE 73     ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 74     ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 75     BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 76     BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 77     REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 78     REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 79     MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
      • FIGURE 80     MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 81     KEY GROWTH STRATEGIES, (2016-2018)
      • FIGURE 82     SWOT: ABBVIE CONTRACT MANUFACTURING.
      • FIGURE 83     SWOT: AENOVA HOLDING GMBH
      • FIGURE 84     SWOT: AMRI
      • FIGURE 85     SWOT: ALMAC
      • FIGURE 86     SWOT: CAMBREX CORPORATION
      • FIGURE 87     SWOT: FAMAR S.A.
      • FIGURE 88     SWOT: GLAXOSMITHKLINE PLC
      • FIGURE 89     SWOT: LONZA GROUP
      • FIGURE 90     SWOT: PATHEON N.V.
      • FIGURE 91     SWOT: PFIZER CENTREONE
      • FIGURE 92     SWOT: RECIPHARM
      • FIGURE 93     SWOT: WUXI STA

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AARTHI DRUGS LTD.
      • 2     ABBVIE CONTRACT MANUFACTURING
      • 3     ACCUPAC, INC. (J.H WHITNEY CAPITAL PARTNERS LLC)
      • 4     ACIC PHARMACEUTICAL INC.
      • 5     AENOVA HOLDING GMBH
      • 6     AESICA PHARMACEUTICALS LTD (CONSORT MEDICAL)
      • 7     AJINOMOTO BIO-PHARMA SERVICES
      • 8     AKORN, INC.
      • 9     ALBANY MOLECULAR RESEARCH INC. (CARLYLE GROUP & GTCR)
      • 10     ALCAMI CORPORATION
      • 11     ALLIANCE CONTRACT PHARMA LLC
      • 12     ALMAC GROUP
      • 13     ALPEX PHARMA S.A.
      • 14     AMBIO PHARMA
      • 15     AMPAC FINE CHEMICALS
      • 16     A.M.S.A. S.P.A.&
      • 17     AMR PHARMA INDIA PRIVATE LIMITED
      • 18     ANI PHARMACEUTICALS, INC.
      • 19     ARDENA GROUP
      • 20     ARTESAN PHARMA GMBH
      • 21     ASYMCHEM LABORATORIES, INC.
      • 22     AVARA PHARMACEUTICAL SERVICES
      • 23     BACHEM HOLDING AG
      • 24     BIOCON LIMITED
      • 25     BIOMAXPHARMA
      • 26     CADILA PHARMACEUTICALS LTD.
      • 27     CAMBREX CORPORATION
      • 28     CERBIOS PHARMA S.A.
      • 29     CHAMBIO CO., LTD.
      • 30     CHEMCON GMBH
      • 31     CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. (CCPC)
      • 32     CIRON DRUGS AND PHARMACEUTICALS PVT LTD.
      • 33     CORDEN PHARMA GMBH
      • 34     CORE RX, INC.
      • 35     CUSTOM PHARMA SERVICES
      • 36     DAITO PHARMACEUTICAL CO., LTD.
      • 37     DALTON PHARMA SERVICE
      • 38     DELPHARM SAS
      • 39     DPT LABORATORIES, LTD. (MYLAN N.V.)
      • 40     DR. REDDY'S LABORATORIES LTD.
      • 41     ELPEN PHARMACEUTICAL CO. INC.
      • 42     ELYSIUM PHARMACEUTICALS LTD.
      • 43     EUTICALS
      • 44     EVER NEURO PHARMA GMBH
      • 45     EVONIK INDUSTRIES AG
      • 46     FAMAR S.A.
      • 47     FAREVA GROUP
      • 48     FERMION OY.
      • 49     FLAMMA S.P.A
      • 50     FUJI CHEMICAL INDUSTRY CO.,LTD
      • 51     GALENICUM HEALTH, S.L.
      • 52     GP PHARM SA
      • 53     GROUPE PARIMA INC.
      • 54     GSK CONTRACT MANUFACTURING
      • 55     GVK BIOSCIENCES PVT LTD.
      • 56     HBM PHARMA S.R.O
      • 57     HERAUES HOLDING GMBH
      • 58     HETERO DRUGS
      • 59     ICROM S.P.A
      • 60     IND-SWIFT LABORATORIES LTD.
      • 61     JOHNSON MATTHEY PHARMA SERVICES  INC.
      • 62     JUBILANT LIFESCIENCES
      • 63     KERN PHARMA, S.L.
      • 64     KLEOS PHARMACEUTICAL INC.
      • 65     KOÇAK FARMA PHARMACEUTICAL
      • 66     KOLMAR KOREA CO., LTD.
      • 67     KWIZDA PHARMA GMBH.
      • 68     LOGOS PHARMA
      • 69     LONZA GROUP LTD
      • 70     LOTUS PHARMACEUTICAL CO., LTD.
      • 71     LSNE CONTRACT MANUFACTURING
      • 72     MADRAS PHARMACEUTICALS PVT LTD
      • 73     MC GUFF PHARMACEUTICALS
      • 74     MERCK SAFC (MERCK & CO. INC)
      • 75     METRICS CONTRACT SERVICES (MAYNE PHARMA INC)
      • 76     MIKART
      • 77     MINT LIFESCIENCES PVT LTD.
      • 78     MSN LABORATORIES PVT LTD.
      • 79     NAUTILUS PHARMA
      • 80     NECTAR LIFESCIENCES LTD.
      • 81     NEOLPHARMA INC.
      • 82     NEXTAR CHEMPHARMA SOLUTIONS LTD.
      • 83     NEXTPHARMA TECHNOLOGIES HOLDING LIMITED
      • 84     NIPRO PHARMA CORPORATION
      • 85     OLON S.P.A
      • 86     ORION PHARMA LTD
      • 87     PATHEON N.V. (THERMOFISHER)
      • 88     PFIZER CENTREONE (PFIZER INC.)
      • 89     PHARMA SYNTH FORMULATIONS LIMITED
      • 90     PHARMAPAC UK LTD., (INYX, INC.)
      • 91     PILLAR5 PHARMA INC.
      • 92     PIRAMAL PHARMA SOLUTIONS
      • 93     POLPHARMA SA PHARMACEUTICAL.
      • 94     PORTON PHARMA SOLUTIONS LTD.
      • 95     RECIPHARM AB
      • 96     SAI LIFE SCIENCE LTD.
      • 97     SAIN MEDICAMENTS PVT LTD.
      • 98     SANECA PHARMACEUTICAL A.S.
      • 99     SANOFI CEPIA
      • 100     SCINOPHARM TAIWAN LTD.
      • 101     SEQENS (NOVACAP)
      • 102     SIEGFRIED AG
      • 103     SK BIOTEK CO.,LTD
      • 104     SOIGNER PHARMA
      • 105     SOPHARMA PHARMA PLC.
      • 106     STASON PHARMACEUTICALS, INC.
      • 107     STERLING PHARMA SOLUTIONS
      • 108     SUPRIYA LIFESCIENCE LTD.
      • 109     SUREPHARMA SERVICES LTD.
      • 110     SYNOKEM PHARMACEUTICALS LTD.
      • 111     TAJ ANDO PHARMACEUTICALS
      • 112     TEMAD CO.
      • 113     TAPI (TEVA PHARMACEUTICAL INDUSTRIES LTD.)
      • 114     UBI PHARMA INC.
      • 115     VALPHARMA S.P.A
      • 116     VENUS PHARMA GMBH
      • 117     VIVIMED LABS LTD
      • 118     WOCKHARDT LTD.
      • 119     WOODFIELD PHARMACEUTICAL LLC
      • 120     WUXI STA PHARMACEUTICAL (WUXI APPTEC+STA PHARMACEUTICAL)
      • 121     YASH PHARMA LABORATORIES PVT LTD.
      • 122     ZACH SYSTEM (ZAMBON COMPANY S.P.A.)
      • 123     ZCL CHEMICALS LTD
      • 124     ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
      • 125     ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.